Page last updated: 2024-10-20

uric acid and Liver Neoplasms

uric acid has been researched along with Liver Neoplasms in 35 studies

Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.

Liver Neoplasms: Tumors or cancer of the LIVER.

Research Excerpts

ExcerptRelevanceReference
"To assess the degree of oxidative stress, we measured plasma ubiquinone-10 percentage (%CoQ-10) in total amounts of ubiquinone-10 in patients with chronic active hepatitis, liver cirrhosis, and hepatocellular carcinoma, and in age-matched control subjects, %CoQ-10 values were 12."7.70Plasma ubiquinone to ubiquinol ratio in patients with hepatitis, cirrhosis, and hepatoma, and in patients treated with percutaneous transluminal coronary reperfusion. ( Yamamoto, Y; Yamashita, S, 1999)
"Purine not only acts as a metabolic substrate of XOR for UA production, but it induces inflammation through IFN-γ secretion that stimulates UA production through elevation of XOR expression."4.12Purine-Induced IFN-γ Promotes Uric Acid Production by Upregulating Xanthine Oxidoreductase Expression. ( Huang, D; Li, X; Liang, B; Lin, Z; Song, X; Su, T; Wang, H; Wang, J; Xie, L, 2022)
" The Child-Pugh score, preoperative serum uric acid and proteinuria may be used to predict the risk of post-TACE AKI in HCC patients undergo TACE."3.80Prognostic factors for acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma. ( Ding, Y; Du, L; Hao, L; Hou, C; Lu, D; Lv, W; Wang, R; Zhou, C, 2014)
"Uric acid values in serum have been analyzed as one of the markers to predict cellular damage due to ischemia reperfusion injury in the field of organ transplantation."3.70Evaluation of serum uric acid changes in different forms of hepatic vascular inflow occlusion in human liver surgeries. ( Ikarashi, Y; Ishizaki, M; Kogure, K; Kuwano, H; Makuuchi, M; Maruyama, Y; Nemoto, M; Tatemoto, K, 1999)
"To assess the degree of oxidative stress, we measured plasma ubiquinone-10 percentage (%CoQ-10) in total amounts of ubiquinone-10 in patients with chronic active hepatitis, liver cirrhosis, and hepatocellular carcinoma, and in age-matched control subjects, %CoQ-10 values were 12."3.70Plasma ubiquinone to ubiquinol ratio in patients with hepatitis, cirrhosis, and hepatoma, and in patients treated with percutaneous transluminal coronary reperfusion. ( Yamamoto, Y; Yamashita, S, 1999)
"A 52-year-old man with retroperitoneal nodal, lung, and liver metastases from choriocarcinoma received chemotherapy with etoposide, cisplatin, and bleomycin."3.70Acute tumor lysis syndrome with choriocarcinoma. ( Blanke, CD; Hemmer, MP; Witte, RS, 2000)
"Zajdela ascite hepatoma transplanted to the abdominal cavity of Vistar rats was used as a model of tumor growth."1.39[Effect of Zajdela ascite hepatoma growth on the extracellular antioxidant system of tumor bearer]. ( Naumov, AA; Potselueva, MM; Shatalin, IuV; Sukhomlin, TK; Zinatullina, GG, 2013)
"Seven pancreatic cancer cell lines were analyzed for MICA/B expression by flow cytometry and for their sensitivity to NK-92 cell killing by a 51Cr release assay."1.37Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression. ( Gattuso, P; Groh, V; Kaufman, HL; Plate, J; Prinz, RA; Rao, GS; Spies, T; Xu, X, 2011)
"Uric acid release was minimal during reperfusion."1.35Decreased hepatosplanchnic antioxidant uptake during hepatic ischaemia/reperfusion in patients undergoing liver resection. ( Bast, A; Dejong, CH; Fischer, MA; Koek, GH; van de Poll, MC, 2008)
"Hepatomegaly was present in 39 out of 40, while 11 out of 27 reported patients had marked hepatomegaly (> 10 cm below the costal margin in the midclavicular line)."1.29The long-term outcome of patients with glycogen storage disease type Ia. ( Smit, GP, 1993)
"A diagnosis of acute renal failure was established within 14 to 70 hours after hepatic artery ligation."1.26Acute renal failure after ligation of the hepatic artery. ( Carrillo, M; Fortner, JG; Kallum, B; Kim, DK; Penneman, R; Scheiner, E, 1976)

Research

Studies (35)

TimeframeStudies, this research(%)All Research%
pre-199013 (37.14)18.7374
1990's6 (17.14)18.2507
2000's5 (14.29)29.6817
2010's7 (20.00)24.3611
2020's4 (11.43)2.80

Authors

AuthorsStudies
Wang, H3
Xie, L1
Song, X1
Wang, J5
Li, X11
Lin, Z1
Su, T1
Liang, B1
Huang, D1
Yu, S1
Li, Z3
Tu, L1
Pu, Y1
Yan, D1
Wang, X6
Zheng, X1
Yu, J1
Hayashi, M1
Yamada, S1
Tanabe, H1
Takami, H1
Inokawa, Y1
Sonohara, F1
Shimizu, D1
Hattori, N1
Kanda, M1
Tanaka, C1
Nakayama, G1
Koike, M1
Fujiwara, M1
Kodera, Y1
Nguépy Keubo, FR1
Mboua, PC1
Djifack Tadongfack, T1
Fokouong Tchoffo, E1
Tasson Tatang, C1
Ide Zeuna, J1
Noupoue, EM1
Tsoplifack, CB1
Folefack, GO1
Kettani, M1
Bandelier, P1
Huo, J1
Li, H4
Yu, D1
Arulsamy, N1
AlAbbad, S1
Sardot, T1
Lekashvili, O1
Decato, D1
Lelj, F1
Alexander Ross, JB1
Rosenberg, E1
Nazir, H1
Muthuswamy, N1
Louis, C1
Jose, S1
Prakash, J1
Buan, MEM1
Flox, C1
Chavan, S1
Shi, X1
Kauranen, P1
Kallio, T1
Maia, G1
Tammeveski, K1
Lymperopoulos, N1
Carcadea, E1
Veziroglu, E1
Iranzo, A1
M Kannan, A1
Arunamata, A1
Tacy, TA1
Kache, S1
Mainwaring, RD1
Ma, M1
Maeda, K1
Punn, R1
Noguchi, S1
Hahn, S3
Iwasa, Y3
Ling, J2
Voccio, JP2
Kim, Y3
Song, J3
Bascuñán, J2
Chu, Y1
Tomita, M1
Cazorla, M1
Herrera, E1
Palomeque, E1
Saud, N1
Hoplock, LB1
Lobchuk, MM1
Lemoine, J1
Henson, MA1
Unsihuay, D1
Qiu, J1
Swaroop, S1
Nagornov, KO1
Kozhinov, AN1
Tsybin, YO1
Kuang, S1
Laskin, J1
Zin, NNINM1
Mohamad, MN1
Roslan, K1
Abdul Wafi, S1
Abdul Moin, NI1
Alias, A1
Zakaria, Y1
Abu-Bakar, N1
Naveed, A1
Jilani, K1
Siddique, AB1
Akbar, M1
Riaz, M1
Mushtaq, Z1
Sikandar, M1
Ilyas, S1
Bibi, I1
Asghar, A1
Rasool, G1
Irfan, M1
Li, XY1
Zhao, S1
Fan, XH1
Chen, KP1
Hua, W1
Liu, ZM1
Xue, XD1
Zhou, B1
Zhang, S2
Xing, YL1
Chen, MA1
Sun, Y1
Neradilek, MB1
Wu, XT1
Zhang, D2
Huang, W1
Cui, Y1
Yang, QQ1
Li, HW1
Zhao, XQ1
Hossein Rashidi, B1
Tarafdari, A1
Ghazimirsaeed, ST1
Shahrokh Tehraninezhad, E1
Keikha, F1
Eslami, B1
Ghazimirsaeed, SM1
Jafarabadi, M1
Silvani, Y1
Lovita, AND1
Maharani, A1
Wiyasa, IWA1
Sujuti, H1
Ratnawati, R1
Raras, TYM1
Lemin, AS1
Rahman, MM1
Pangarah, CA1
Kiyu, A1
Zeng, C2
Du, H1
Lin, D1
Jalan, D1
Rubagumya, F1
Hopman, WM1
Vanderpuye, V1
Lopes, G1
Seruga, B1
Booth, CM1
Berry, S1
Hammad, N1
Sajo, EA1
Okunade, KS1
Olorunfemi, G1
Rabiu, KA1
Anorlu, RI1
Xu, C2
Xiang, Y1
Xu, X2
Zhou, L2
Dong, X1
Tang, S1
Gao, XC1
Wei, CH1
Zhang, RG1
Cai, Q1
He, Y1
Tong, F1
Dong, JH1
Wu, G1
Dong, XR1
Tang, X1
Tao, F1
Xiang, W1
Zhao, Y2
Jin, L1
Tao, H1
Lei, Y1
Gan, H1
Huang, Y1
Chen, Y3
Chen, L3
Shan, A1
Zhao, H2
Wu, M2
Ma, Q1
Zhang, E1
Zhang, J3
Li, Y5
Xue, F1
Deng, L1
Liu, L2
Yan, Z2
Wang, Y2
Meng, J1
Chen, G2
Anastassiadou, M1
Bernasconi, G1
Brancato, A1
Carrasco Cabrera, L1
Greco, L1
Jarrah, S1
Kazocina, A1
Leuschner, R1
Magrans, JO1
Miron, I1
Nave, S1
Pedersen, R1
Reich, H1
Rojas, A1
Sacchi, A1
Santos, M1
Theobald, A1
Vagenende, B1
Verani, A1
Du, L2
Liu, X1
Ren, Y1
Li, J7
Li, P1
Jiao, Q1
Meng, P1
Wang, F2
Wang, YS1
Wang, C3
Zhou, X2
Wang, W1
Wang, S2
Hou, J1
Zhang, A1
Lv, B1
Gao, C1
Pang, D1
Lu, K1
Ahmad, NH1
Wang, L1
Zhu, J2
Zhang, L2
Zhuang, T1
Tu, J1
Zhao, Z1
Qu, Y1
Yao, H1
Lee, DF1
Shen, J3
Wen, L1
Huang, G2
Xie, X1
Zhao, Q1
Hu, W1
Zhang, Y4
Wu, X1
Lu, J2
Li, M1
Li, W2
Wu, W1
Du, F1
Ji, H1
Yang, X2
Xu, Z1
Wan, L1
Wen, Q1
Cho, CH1
Zou, C1
Xiao, Z1
Liao, J1
Su, X1
Bi, Z1
Su, Q1
Huang, H1
Wei, Y2
Gao, Y2
Na, KJ1
Choi, H1
Oh, HR1
Kim, YH1
Lee, SB1
Jung, YJ1
Koh, J1
Park, S1
Lee, HJ1
Jeon, YK1
Chung, DH1
Paeng, JC1
Park, IK1
Kang, CH1
Cheon, GJ1
Kang, KW1
Lee, DS1
Kim, YT1
Pajuelo-Lozano, N1
Alcalá, S1
Sainz, B1
Perona, R1
Sanchez-Perez, I1
Logotheti, S1
Marquardt, S1
Gupta, SK1
Richter, C1
Edelhäuser, BAH1
Engelmann, D1
Brenmoehl, J1
Söhnchen, C1
Murr, N1
Alpers, M1
Singh, KP1
Wolkenhauer, O1
Heckl, D1
Spitschak, A1
Pützer, BM1
Liao, Y1
Cheng, J2
Kong, X1
Li, S1
Zhang, M4
Zhang, H1
Yang, T2
Dong, Y1
Xu, Y1
Yuan, Z1
Cao, J1
Zheng, Y1
Luo, Z1
Mei, Z1
Yao, Y1
Liu, Z2
Liang, C1
Yang, H1
Song, Y1
Yu, K1
Zhu, C1
Huang, Z1
Qian, J1
Ge, J1
Hu, J2
Liu, Y4
Mi, Y1
Kong, H1
Xi, D1
Yan, W1
Luo, X1
Ning, Q1
Chang, X2
Zhang, T2
Wang, Q2
Rathore, MG1
Reddy, K1
Chen, H1
Shin, SH1
Ma, WY1
Bode, AM1
Dong, Z1
Mu, W1
Liu, C3
Gao, F1
Qi, Y1
Lu, H1
Zhang, X4
Cai, X1
Ji, RY1
Hou, Y3
Tian, J2
Shi, Y1
Ying, S1
Tan, M1
Feng, G1
Kuang, Y1
Chen, D1
Wu, D3
Zhu, ZQ1
Tang, HX1
Shi, ZE1
Kang, J1
Liu, Q1
Qi, J2
Mu, J1
Cong, Z1
Chen, S2
Fu, D1
Celestrin, CP1
Rocha, GZ1
Stein, AM1
Guadagnini, D1
Tadelle, RM1
Saad, MJA1
Oliveira, AG1
Bianconi, V1
Bronzo, P1
Banach, M1
Sahebkar, A1
Mannarino, MR1
Pirro, M1
Patsourakos, NG1
Kouvari, M1
Kotidis, A1
Kalantzi, KI1
Tsoumani, ME1
Anastasiadis, F1
Andronikos, P1
Aslanidou, T1
Efraimidis, P1
Georgiopoulos, A1
Gerakiou, K1
Grigoriadou-Skouta, E1
Grigoropoulos, P1
Hatzopoulos, D1
Kartalis, A1
Lyras, A1
Markatos, G1
Mikrogeorgiou, A1
Myroforou, I1
Orkopoulos, A1
Pavlidis, P1
Petras, C1
Riga, M1
Skouloudi, M1
Smyrnioudis, N1
Thomaidis, K1
Tsikouri, GE1
Tsikouris, EI1
Zisimos, K1
Vavoulis, P1
Vitali, MG1
Vitsas, G1
Vogiatzidis, C1
Chantanis, S1
Fousas, S1
Panagiotakos, DB1
Tselepis, AD1
Jungen, C1
Alken, FA1
Eickholt, C1
Scherschel, K1
Kuklik, P1
Klatt, N1
Schwarzl, J1
Moser, J1
Jularic, M1
Akbulak, RO1
Schaeffer, B1
Willems, S1
Meyer, C1
Nowak, JK1
Szczepanik, M1
Trypuć, M1
Pogorzelski, A1
Bobkowski, W1
Grytczuk, M1
Minarowska, A1
Wójciak, R1
Walkowiak, J1
Lu, Y1
Xi, J1
Li, C1
Chen, W2
Hu, X1
Zhang, F1
Wei, H1
Wang, Z1
Gurzu, S1
Jung, I1
Sugimura, H2
Stefan-van Staden, RI1
Yamada, H1
Natsume, H1
Iwashita, Y1
Szodorai, R1
Szederjesi, J1
Yari, D1
Ehsanbakhsh, Z1
Validad, MH1
Langroudi, FH1
Esfandiari, H1
Prager, A1
Hassanpour, K1
Kurup, SP1
Mets-Halgrimson, R1
Yoon, H1
Zeid, JL1
Mets, MB1
Rahmani, B1
Araujo-Castillo, RV1
Culquichicón, C1
Solis Condor, R1
Efendi, F1
Sebayang, SK1
Astutik, E1
Hadisuyatmana, S1
Has, EMM1
Kuswanto, H1
Foroutan, T1
Ahmadi, F1
Moayer, F1
Khalvati, S1
Zhang, Q2
Lyu, Y1
Huang, J1
Yu, N1
Wen, Z1
Hou, H1
Zhao, T1
Gupta, A1
Khosla, N1
Govindasamy, V1
Saini, A1
Annapurna, K1
Dhakate, SR1
Akkaya, Ö1
Chandgude, AL1
Dömling, A1
Harnett, J1
Oakes, K1
Carè, J1
Leach, M1
Brown, D1
Cramer, H1
Pinder, TA1
Steel, A1
Anheyer, D1
Cantu, J1
Valle, J1
Flores, K1
Gonzalez, D1
Valdes, C1
Lopez, J1
Padilla, V1
Alcoutlabi, M1
Parsons, J1
Núñez, K1
Hamed, M1
Fort, D1
Bruce, D1
Thevenot, P1
Cohen, A1
Weber, P1
Menezes, AMB1
Gonçalves, H1
Perez-Padilla, R1
Jarvis, D1
de Oliveira, PD1
Wehrmeister, FC1
Mir, S1
Wong, J1
Ryan, CM1
Bellingham, G1
Singh, M2
Waseem, R1
Eckert, DJ1
Chung, F1
Hegde, H1
Shimpi, N1
Panny, A1
Glurich, I1
Christie, P1
Acharya, A1
English, KL1
Downs, M1
Goetchius, E1
Buxton, R1
Ryder, JW1
Ploutz-Snyder, R1
Guilliams, M1
Scott, JM1
Ploutz-Snyder, LL1
Martens, C1
Goplen, FK1
Aasen, T1
Gjestad, R1
Nordfalk, KF1
Nordahl, SHG1
Inoue, T1
Soshi, S1
Kubota, M1
Marumo, K1
Mortensen, NP1
Caffaro, MM1
Patel, PR2
Uddin, MJ1
Aravamudhan, S1
Sumner, SJ1
Fennell, TR1
Gal, RL1
Cohen, NJ1
Kruger, D1
Beck, RW1
Bergenstal, RM1
Calhoun, P1
Cushman, T1
Haban, A1
Hood, K1
Johnson, ML1
McArthur, T1
Olson, BA1
Weinstock, RS1
Oser, SM1
Oser, TK1
Bugielski, B1
Strayer, H1
Aleppo, G1
Maruyama, H1
Hirayama, K1
Yamashita, M1
Ohgi, K1
Tsujimoto, R1
Takayasu, M1
Shimohata, H1
Kobayashi, M1
Buscagan, TM1
Rees, DC1
Jaborek, JR1
Zerby, HN1
Wick, MP1
Fluharty, FL1
Moeller, SJ1
Razavi, P1
Dickler, MN1
Shah, PD1
Toy, W1
Brown, DN1
Won, HH1
Li, BT1
Shen, R1
Vasan, N1
Modi, S1
Jhaveri, K1
Caravella, BA1
Patil, S1
Selenica, P1
Zamora, S1
Cowan, AM1
Comen, E1
Singh, A1
Covey, A1
Berger, MF1
Hudis, CA1
Norton, L1
Nagy, RJ1
Odegaard, JI1
Lanman, RB1
Solit, DB1
Robson, ME1
Lacouture, ME1
Brogi, E1
Reis-Filho, JS1
Moynahan, ME1
Scaltriti, M1
Chandarlapaty, S1
Papouskova, K1
Moravcova, M1
Masrati, G1
Ben-Tal, N1
Sychrova, H1
Zimmermannova, O1
Fang, J1
Fan, Y1
Luo, T2
Su, H1
Tsetseris, L1
Anthopoulos, TD1
Liu, SF1
Zhao, K1
Sacan, O1
Turkyilmaz, IB1
Bayrak, BB1
Mutlu, O1
Akev, N1
Yanardag, R1
Gruber, S1
Kamnoedboon, P1
Özcan, M1
Srinivasan, M1
Jo, YH1
Oh, HK1
Jeong, SY1
Lee, BG1
Zheng, J1
Guan, H1
Li, D3
Tan, H1
Maji, TK1
J R, A1
Mukherjee, S1
Alexander, R1
Mondal, A1
Das, S1
Sharma, RK1
Chakraborty, NK1
Dasgupta, K1
Sharma, AMR1
Hawaldar, R1
Pandey, M1
Naik, A1
Majumdar, K1
Pal, SK1
Adarsh, KV1
Ray, SK1
Karmakar, D1
Ma, Y2
Gao, W1
Ma, S1
Lin, W1
Zhou, T1
Wu, T1
Wu, Q1
Ye, C1
He, X1
Jiang, F1
Yuan, D1
Chen, Q1
Hong, M1
Chen, K1
Hussain, M1
Razi, SS1
Yildiz, EA1
Zhao, J1
Yaglioglu, HG1
Donato, MD1
Jiang, J1
Jamil, MI1
Zhan, X1
Chen, F1
Cheng, D1
Wu, CT1
Utsunomiya, T1
Ichii, T1
Fujinami, S1
Nakajima, K1
Sanchez, DM1
Raucci, U1
Ferreras, KN1
Martínez, TJ1
Mordi, NA1
Mordi, IR1
Singh, JS1
McCrimmon, RJ1
Struthers, AD1
Lang, CC1
Wang, XW1
Yuan, LJ1
Yang, Y1
Chen, WF1
Luo, R1
Yang, K1
Amarasiri, SS1
Attanayake, AP1
Arawwawala, LDAM1
Jayatilaka, KAPW1
Mudduwa, LKB1
Ogunsuyi, O2
Akanni, O1
Alabi, O1
Alimba, C1
Adaramoye, O1
Cambier, S1
Eswara, S1
Gutleb, AC1
Bakare, A1
Gu, Z1
Cong, J1
Pellegrini, M1
Palmieri, S1
Ricci, A1
Serio, A1
Paparella, A1
Lo Sterzo, C1
Jadeja, SD1
Vaishnav, J1
Mansuri, MS1
Shah, C1
Mayatra, JM1
Shah, A1
Begum, R1
Song, H2
Lian, Y1
Wan, T1
Schultz-Lebahn, A1
Skipper, MT1
Hvas, AM1
Larsen, OH1
Hijazi, Z1
Granger, CB1
Hohnloser, SH1
Westerbergh, J1
Lindbäck, J1
Alexander, JH1
Keltai, M1
Parkhomenko, A1
López-Sendón, JL1
Lopes, RD1
Siegbahn, A1
Wallentin, L1
El-Tarabany, MS1
Saleh, AA1
El-Araby, IE1
El-Magd, MA1
van Ginkel, MPH1
Schijven, MP1
van Grevenstein, WMU1
Schreuder, HWR1
Pereira, EDM1
da Silva, J1
Carvalho, PDS1
Grivicich, I1
Picada, JN1
Salgado Júnior, IB1
Vasques, GJ1
Pereira, MADS1
Reginatto, FH1
Ferraz, ABF1
Vasilenko, EA1
Gorshkova, EN1
Astrakhantseva, IV1
Drutskaya, MS1
Tillib, SV1
Nedospasov, SA1
Mokhonov, VV1
Nam, YW1
Cui, M1
Orfali, R1
Viegas, A1
Nguyen, M1
Mohammed, EHM1
Zoghebi, KA1
Rahighi, S1
Parang, K1
Patterson, KC1
Kahanovitch, U1
Gonçalves, CM1
Hablitz, JJ1
Staruschenko, A1
Mulkey, DK1
Olsen, ML1
Gu, L1
Cao, X1
Mukhtar, A1
Wu, K1
Zhang, YY1
Zhu, Y1
Lu, DZ1
Dong, W1
Bi, WJ1
Feng, XJ1
Wen, LM1
Sun, H1
Qi, MC1
Chang, CC1
Dinh, TK1
Lee, YA1
Wang, FN1
Sung, YC1
Yu, PL1
Chiu, SC1
Shih, YC1
Wu, CY1
Huang, YD1
Lu, TT1
Wan, D1
Sakizadeh, J1
Cline, JP1
Snyder, MA1
Kiely, CJ1
McIntosh, S1
Jiang, X1
Cao, JW1
Zhao, CK1
Yang, R1
Zhang, QY1
Chen, KJ2
Liu, H1
He, Z1
Chen, B1
Wu, J1
Du, X1
Moore, J1
Blank, BR1
Eksterowicz, J1
Sutimantanapi, D1
Yuen, N1
Metzger, T1
Chan, B1
Huang, T1
Chen, X1
Duong, F1
Kong, W1
Chang, JH1
Sun, J1
Zavorotinskaya, T1
Ye, Q1
Junttila, MR1
Ndubaku, C1
Friedman, LS1
Fantin, VR1
Sun, D1
Fei, P1
Xie, Q1
Jiang, Y1
Feng, H1
Chang, Y1
Kang, H1
Xing, M1
Chen, J1
Shao, Z1
Yuan, C1
Wu, Y1
Allan, R1
Canham, K1
Wallace, R1
Singh, D1
Ward, J1
Cooper, A1
Newcomb, C1
Nammour, S1
El Mobadder, M1
Maalouf, E1
Namour, M1
Namour, A1
Rey, G1
Matamba, P1
Matys, J1
Zeinoun, T1
Grzech-Leśniak, K1
Segabinazi Peserico, C1
Garozi, L1
Zagatto, AM1
Machado, FA1
Hirth, JM1
Dinehart, EE1
Lin, YL1
Kuo, YF1
Nouri, SS1
Ritchie, C1
Volow, A1
Li, B2
McSpadden, S1
Dearman, K1
Kotwal, A1
Sudore, RL1
Ward, L1
Thakur, A1
Kondadasula, SV1
Ji, K1
Schalk, DL1
Bliemeister, E1
Ung, J1
Aboukameel, A1
Casarez, E1
Sloane, BF1
Lum, LG1
Xiao, M1
Feng, X1
Gao, R1
Du, B1
Brooks, T1
Zwirner, J1
Hammer, N1
Ondruschka, B1
Jermy, M1
Luengo, A1
Marzo, I1
Reback, M1
Daubit, IM1
Fernández-Moreira, V1
Metzler-Nolte, N1
Gimeno, MC1
Tonchev, I1
Heberman, D1
Peretz, A1
Medvedovsky, AT1
Gotsman, I1
Rashi, Y1
Poles, L1
Goland, S1
Perlman, GY1
Danenberg, HD1
Beeri, R1
Shuvy, M1
Fu, Q1
Yang, D1
Sarapulova, A1
Pang, Q1
Meng, Y1
Wei, L1
Ehrenberg, H1
Kim, CC1
Jeong, SH1
Oh, KH1
Nam, KT1
Sun, JY1
Ning, J1
Duan, Z1
Kershaw, SV1
Rogach, AL1
Gao, Z1
Wang, T1
Li, Q1
Cao, T1
Guo, L1
Fu, Y1
Seeger, ZL1
Izgorodina, EI1
Hue, S1
Beldi-Ferchiou, A1
Bendib, I1
Surenaud, M1
Fourati, S1
Frapard, T1
Rivoal, S1
Razazi, K1
Carteaux, G1
Delfau-Larue, MH1
Mekontso-Dessap, A1
Audureau, E1
de Prost, N1
Gao, SS1
Duangthip, D1
Lo, ECM1
Chu, CH1
Roberts, W1
Rosenheck, RA1
Miyake, T1
Kimoto, E1
Luo, L1
Mathialagan, S1
Horlbogen, LM1
Ramanathan, R1
Wood, LS1
Johnson, JG1
Le, VH1
Vourvahis, M1
Rodrigues, AD1
Muto, C1
Furihata, K1
Sugiyama, Y1
Kusuhara, H1
Gong, Q1
Song, W1
Sun, B1
Cao, P1
Gu, S1
Sun, X1
Zhou, G1
Toma, C1
Khandhar, S1
Zalewski, AM1
D'Auria, SJ1
Tu, TM1
Jaber, WA1
Cho, J2
Suwandaratne, NS1
Razek, S1
Choi, YH1
Piper, LFJ1
Watson, DF1
Banerjee, S1
Xie, S1
Lindsay, AP1
Bates, FS1
Lodge, TP1
Hao, Y1
Chapovetsky, A1
Liu, JJ1
Welborn, M1
Luna, JM1
Do, T1
Haiges, R1
Miller Iii, TF1
Marinescu, SC1
Lopez, SA1
Compter, I1
Eekers, DBP1
Hoeben, A1
Rouschop, KMA1
Reymen, B1
Ackermans, L1
Beckervordersantforth, J1
Bauer, NJC1
Anten, MM1
Wesseling, P1
Postma, AA1
De Ruysscher, D1
Lambin, P1
Qiang, L1
Yang, S1
Cui, YH1
He, YY1
Kumar, SK1
Jacobus, SJ1
Cohen, AD1
Weiss, M1
Callander, N1
Singh, AK1
Parker, TL1
Menter, A1
Parsons, B1
Kumar, P1
Kapoor, P1
Rosenberg, A1
Zonder, JA1
Faber, E1
Lonial, S1
Anderson, KC1
Richardson, PG1
Orlowski, RZ1
Wagner, LI1
Rajkumar, SV1
Li, G1
Hou, G1
Cui, J1
Xie, H1
Sun, Z1
Fang, Z1
Dunstand-Guzmán, E1
Hallal-Calleros, C1
Hernández-Velázquez, VM1
Canales-Vargas, EJ1
Domínguez-Roldan, R1
Pedernera, M1
Peña-Chora, G1
Flores-Pérez, I1
Kim, MJ1
Han, C1
White, K1
Park, HJ1
Ding, D1
Boyd, K1
Rothenberger, C1
Bose, U1
Carmichael, P1
Linser, PJ1
Tanokura, M1
Salvi, R1
Someya, S1
Samuni, A1
Goldstein, S1
Divya, KP1
Dharuman, V1
Feng, J2
Qian, Y1
Cheng, Q1
Ma, H1
Ren, X1
Wei, Q1
Pan, W1
Guo, J1
Situ, B1
An, T1
Zheng, L1
Augusto, S1
Ratola, N1
Tarín-Carrasco, P1
Jiménez-Guerrero, P1
Turco, M1
Schuhmacher, M1
Costa, S1
Teixeira, JP1
Costa, C1
Syed, A1
Marraiki, N1
Al-Rashed, S1
Elgorban, AM1
Yassin, MT1
Chankhanittha, T1
Nanan, S1
Sorokina, KN1
Samoylova, YV1
Gromov, NV1
Ogorodnikova, OL1
Parmon, VN1
Ye, J1
Liao, W1
Zhang, P1
Nabi, M1
Cai, Y1
Li, F1
Alsbou, EM1
Omari, KW1
Adeosun, WA1
Asiri, AM1
Marwani, HM1
Barral, M1
Jemal-Turki, A1
Beuvon, F1
Soyer, P1
Camparo, P1
Cornud, F1
Atwater, BD1
Jones, WS1
Loring, Z1
Friedman, DJ1
Namburath, M1
Papirio, S1
Moscariello, C1
Di Costanzo, N1
Pirozzi, F1
Alappat, BJ1
Sreekrishnan, TR1
Volpin, F1
Woo, YC1
Kim, H1
Freguia, S1
Jeong, N1
Choi, JS1
Phuntsho, S1
Shon, HK1
Domínguez-Zambrano, E1
Pedraza-Chaverri, J1
López-Santos, AL1
Medina-Campos, ON1
Cruz-Rivera, C1
Bueno-Hernández, F1
Espinosa-Cuevas, A1
Bulavaitė, A1
Dalgediene, I1
Michailoviene, V1
Pleckaityte, M1
Sauerbier, P1
Köhler, R1
Renner, G1
Militz, H1
Han, X1
Yang, J1
Guo, Z1
Hashem, SG1
Elsaady, MM1
Afify, HG1
Omer, WE1
Youssef, AO1
El-Kemary, M1
Attia, MS1
Potselueva, MM1
Naumov, AA1
Sukhomlin, TK1
Zinatullina, GG1
Shatalin, IuV1
Zhou, C1
Wang, R1
Ding, Y1
Hou, C1
Lu, D1
Hao, L1
Lv, W1
Boudin, L1
Patient, M1
Roméo, E1
Bladé, JS1
de Jauréguiberry, JP1
Rao, GS1
Groh, V1
Spies, T1
Gattuso, P1
Kaufman, HL1
Plate, J1
Prinz, RA1
Ko, YH1
Verhoeven, HA1
Lee, MJ1
Corbin, DJ1
Vogl, TJ1
Pedersen, PL1
WU, C1
BAUER, JM1
DELAMIRANDE, G1
van de Poll, MC1
Dejong, CH1
Fischer, MA1
Bast, A1
Koek, GH1
Di Rocco, M1
Calevo, MG1
Taro', M1
Melis, D1
Allegri, AE1
Parenti, G1
Lucagne, F1
Fallourd, P1
Redelsperger, PY1
Courtin, A1
Libeskind, M1
Usami, M1
Furuchi, K1
Kasahara, H1
Haji, S1
Kitani, G1
Iso, A1
Sun, K1
Sou, E1
Zheng, JH1
Sakata, K1
Smit, GP1
Loguercio, C1
Nardone, G1
Sicolo, P1
Cuomo, R1
Del Vecchio, C1
Budillon, G1
Galus, M1
Kogure, K1
Ishizaki, M1
Nemoto, M1
Kuwano, H1
Tatemoto, K1
Maruyama, Y1
Ikarashi, Y1
Makuuchi, M1
Yamamoto, Y1
Yamashita, S1
Santin, AD1
Hermonat, PL1
Ravaggi, A1
Bellone, S1
Cowan, C1
Coke, C1
Pecorelli, S1
Cannon, MJ1
Parham, GP1
Blanke, CD1
Hemmer, MP1
Witte, RS1
Yamamoto, T2
Moriwaki, Y2
Takahashi, S2
Tsutsumi, Z1
Ka, T1
Hada, T2
Weinberger, A1
Pinkhas, J1
Sperling, O1
De Vries, A1
Kim, DK1
Penneman, R1
Kallum, B1
Carrillo, M1
Scheiner, E1
Fortner, JG1
Jeng, KS1
Ching, HJ1
Gosset, D1
Clément, O1
Flechaire, A1
Viart, R1
Valmary, J1
Daly, JP1
Nakano, T1
Amuro, Y1
Higashino, K1
Magoula, I1
Tsapas, G1
Garyfallos, A1
Kountouras, J1
Skibba, JL1
Quebbeman, EJ1
Kalbfleisch, JH1
Fukushima, M1
Ishikawa, Y1
Horimai, T1
Adachi, M1
Bloomenthal, ED1
Spellberg, MA1
Horn, GW1
Chandler, FW1
Fletcher, OJ1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 1, Open-label, Randomized, Two-period, Two-treatment, Crossover Study to Evaluate the Effects of Food on the Pharmacokinetics of Urate After a Single Dose of Inosine in Healthy Male Subjects[NCT02614469]Phase 118 participants (Actual)Interventional2015-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

AUC (0-inf): Area Under the Serum Concentration-time Curve From Time 0 to Infinity

(NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose

Interventionmg*hr/dL (Mean)
Inosine Fed2040
Inosine Fasted2031

AUC (0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t (Time of Last Quantifiable Plasma Concentration)

(NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose

Interventionmg*hr/dL (Mean)
Inosine Fed267
Inosine Fasted268

Baseline Corrected AUC (0-inf): Baseline Corrected Area Under the Serum Concentration-time Curve From Time 0 to Infinity

Correction for individual endogenous urate levels was done by subtracting the individual mean endogenous baseline concentration prior to dosing from each post-dose concentration in the profile. The two samples collected at -12 h and 0 h (pre-dose) before the meal were used to measure the mean endogenous baseline concentrations in each dosing period (periods 1 and 2). (NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, and 48 hrs post-dose

Interventionmg*hr/dL (Mean)
Inosine Fed80.4
Inosine Fasted83.0

Baseline Corrected AUC (0-t): Baseline Corrected Area Under the Serum Concentration-time Curve From Time 0 to Time t (Time of Last Quantifiable Serum Concentration)

Correction for individual endogenous urate levels was done by subtracting the individual mean endogenous baseline concentration prior to dosing from each post-dose concentration in the profile. The two samples collected at -12 h and 0 h (pre-dose) before the meal were used to measure the mean endogenous baseline concentrations in each dosing period (periods 1 and 2). Negative concentrations were set to zero. (NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose

Interventionmg*hr/dL (Mean)
Inosine Fed36.1
Inosine Fasted39.3

Baseline Corrected Cmax: Baseline Corrected Maximum Serum Concentration

Correction for individual endogenous urate levels was done by subtracting the individual mean endogenous baseline concentration prior to dosing from each post-dose concentration in the profile. The two samples collected at -12 h and 0 h (pre-dose) before the meal were used to measure the mean endogenous baseline concentrations in each dosing period (periods 1 and 2). Negative concentrations were set to zero. (NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose

Interventionmg/dL (Mean)
Inosine Fed1.73
Inosine Fasted1.65

Baseline Corrected T1/2: Baseline Corrected Apparent Terminal Half-life

Correction for individual endogenous urate levels was done by subtracting the individual mean endogenous baseline concentration prior to dosing from each post-dose concentration in the profile. The two samples collected at -12 h and 0 h (pre-dose) before the meal were used to measure the mean endogenous baseline concentrations in each dosing period (periods 1 and 2). (NCT02614469)
Timeframe: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose

Interventionhr (Mean)
Inosine Fed44.3
Inosine Fasted44.7

Baseline Corrected Tmax: Baseline Corrected Time of Maximum Serum Concentration

Correction for individual endogenous urate levels was done by subtracting the individual mean endogenous baseline concentration prior to dosing from each post-dose concentration in the profile. The two samples collected at -12 h and 0 h (pre-dose) before the meal were used to measure the mean endogenous baseline concentrations in each dosing period (periods 1 and 2). (NCT02614469)
Timeframe: -12 to 0 h pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, and 48 hrs post-dose

Interventionhr (Median)
Inosine Fed3.0
Inosine Fasted3.0

Cmax: Maximum Observed Serum Urate Concentration

(NCT02614469)
Timeframe: -12 to 0 hrs pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hrs post-dose

Interventionmg/dL (Mean)
Inosine Fed6.6
Inosine Fasted6.4

Safety Assessment (Vital Signs)

Number of participants with clinically significant findings in vital signs by investigator after study drug administration. (NCT02614469)
Timeframe: Up to 10 days after first study drug administration at Day 1 of Period 1

Interventionparticipants (Number)
Inosine Fed0
Inosine Fasted0

Safety Assessment: Adverse Events

Number of participants with adverse events after study drug administration (NCT02614469)
Timeframe: Up to 10 days after first study drug administration at Day 1 of Period 1

Interventionparticipants (Number)
Inosine Fed0
Inosine Fasted0

T1/2: Apparent Terminal Half-life

(NCT02614469)
Timeframe: -12 to 0 pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose

Interventionhr (Mean)
Inosine Fed242
Inosine Fasted241

Tmax: Time of Maximum Serum Concentration

(NCT02614469)
Timeframe: -12 to 0 hr pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose

Interventionhr (Median)
Inosine Fed3.0
Inosine Fasted3.0

Reviews

1 review available for uric acid and Liver Neoplasms

ArticleYear
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021

Trials

1 trial available for uric acid and Liver Neoplasms

ArticleYear
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021

Other Studies

34 other studies available for uric acid and Liver Neoplasms

ArticleYear
Purine-Induced IFN-γ Promotes Uric Acid Production by Upregulating Xanthine Oxidoreductase Expression.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Hepatocytes; Humans; Inflammation; Interferon-gamma; Ju

2022
Uricase sensitizes hepatocellular carcinoma cells to 5-fluorouracil through uricase-uric acid-UMP synthase axis.
    Journal of physiology and biochemistry, 2022, Volume: 78, Issue:3

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Humans; Liver

2022
High Serum Uric Acid Levels Could Be a Risk Factor of Hepatocellular Carcinoma Recurrences.
    Nutrition and cancer, 2021, Volume: 73, Issue:6

    Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Risk Factors;

2021
Overexpression of Uric Acid Transporter SLC2A9 Inhibits Proliferation of Hepatocellular Carcinoma Cells.
    Oncology research, 2019, May-07, Volume: 27, Issue:5

    Topics: Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Cell Proliferation; Gene Expression Regulation

2019
Determination of uric acid in serum using an optical sensor based on binuclear Pd(II) 2-pyrazinecarboxamide-bipyridine doped in a sol gel matrix.
    Talanta, 2019, Jul-01, Volume: 199

    Topics: 2,2'-Dipyridyl; Carcinoma, Hepatocellular; Cardiovascular Diseases; Coordination Complexes; Gels; Hu

2019
[Effect of Zajdela ascite hepatoma growth on the extracellular antioxidant system of tumor bearer].
    Tsitologiia, 2013, Volume: 55, Issue:5

    Topics: Animals; Antioxidants; Ascites; Carcinoma, Hepatocellular; Ceruloplasmin; Disease Models, Animal; Li

2013
Prognostic factors for acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma.
    International journal of clinical and experimental pathology, 2014, Volume: 7, Issue:5

    Topics: Acute Kidney Injury; Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; China;

2014
[Hyperleucocytosis with acute uric acid nephropathy in a patient with hepatocellular carcinoma].
    Presse medicale (Paris, France : 1983), 2017, Volume: 46, Issue:2 Pt 1

    Topics: Acute Kidney Injury; Aged; Carcinoma, Hepatocellular; Humans; Leukocytosis; Liver Neoplasms; Male; U

2017
Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression.
    BMC cancer, 2011, May-23, Volume: 11

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic

2011
A translational study "case report" on the small molecule "energy blocker" 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside.
    Journal of bioenergetics and biomembranes, 2012, Volume: 44, Issue:1

    Topics: Adolescent; Ammonia; Antineoplastic Agents, Alkylating; Carcinoma, Hepatocellular; Energy Metabolism

2012
Catabolism of xanthine and uracil in tumor-bearing rats.
    Cancer research, 1962, Volume: 22

    Topics: Animals; Carcinoma 256, Walker; Carcinoma, Hepatocellular; Hydantoins; Liver Neoplasms; Neoplasms; N

1962
PROTEIN-BOUND DYE AND PURINE-CATABOLYZING ENZYMES IN PARENCHYMAL AND NONPARENCHYMAL CELLS OF RATS FED 4-DIMETHYLAMINOAZOBENZENE.
    Cancer research, 1964, Volume: 24

    Topics: Azo Compounds; Carcinogens; Enzymes; Guanine; Histocytochemistry; Liver; Liver Neoplasms; N-Glycosyl

1964
Decreased hepatosplanchnic antioxidant uptake during hepatic ischaemia/reperfusion in patients undergoing liver resection.
    Clinical science (London, England : 1979), 2008, Volume: 114, Issue:8

    Topics: Aged; Antioxidants; Female; Hepatectomy; Humans; Intraoperative Period; Liver; Liver Neoplasms; Male

2008
Hepatocellular adenoma and metabolic balance in patients with type Ia glycogen storage disease.
    Molecular genetics and metabolism, 2008, Volume: 93, Issue:4

    Topics: Adenoma, Liver Cell; Adolescent; Adult; Body Mass Index; Case-Control Studies; Child; Child, Prescho

2008
[Schwartz-Bartter syndrome with hypouricemia due to an anaplastic small cell tracheal tumor].
    La Nouvelle presse medicale, 1980, Oct-11, Volume: 9, Issue:37

    Topics: Female; Humans; Inappropriate ADH Syndrome; Liver Neoplasms; Middle Aged; Sodium; Tracheal Neoplasms

1980
The effect of partial hepatectomy on blood purine levels in rats and patients.
    Advances in experimental medicine and biology, 1994, Volume: 370

    Topics: Adenosine Triphosphate; Animals; Chromatography, High Pressure Liquid; DNA; Hemangioma; Hepatectomy;

1994
The long-term outcome of patients with glycogen storage disease type Ia.
    European journal of pediatrics, 1993, Volume: 152 Suppl 1

    Topics: Adenoma; Adolescent; Adult; Aged; Apolipoproteins; Blood Glucose; Child; Cholesterol; Female; Glycog

1993
Intravenous load of fructose and fructose 1,6-diphosphate: effects on uricemia in patients with nonalcoholic liver disease.
    The American journal of gastroenterology, 1996, Volume: 91, Issue:3

    Topics: Adult; Carcinoma, Hepatocellular; Diagnosis, Differential; Female; Fructose; Fructose-Bisphosphatase

1996
Liver failure due to metastatic small-cell carcinoma of the lung.
    Mayo Clinic proceedings, 1997, Volume: 72, Issue:8

    Topics: Alanine Transaminase; Carcinoma, Small Cell; Fatal Outcome; Female; Humans; L-Lactate Dehydrogenase;

1997
Evaluation of serum uric acid changes in different forms of hepatic vascular inflow occlusion in human liver surgeries.
    Life sciences, 1999, Volume: 64, Issue:5

    Topics: Adolescent; Adult; Aged; Biomarkers; Child; Female; Hepatectomy; Humans; Intraoperative Complication

1999
Plasma ubiquinone to ubiquinol ratio in patients with hepatitis, cirrhosis, and hepatoma, and in patients treated with percutaneous transluminal coronary reperfusion.
    BioFactors (Oxford, England), 1999, Volume: 9, Issue:2-4

    Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Ascorbic Acid; beta Carotene; Biliru

1999
Development and therapeutic effect of adoptively transferred T cells primed by tumor lysate-pulsed autologous dendritic cells in a patient with metastatic endometrial cancer.
    Gynecologic and obstetric investigation, 2000, Volume: 49, Issue:3

    Topics: Aged; CD56 Antigen; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Dendritic Cells; Endometr

2000
Acute tumor lysis syndrome with choriocarcinoma.
    Southern medical journal, 2000, Volume: 93, Issue:9

    Topics: Acidosis; Acute Disease; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents,

2000
Effect of inosine on the plasma concentration of uridine and purine bases.
    Metabolism: clinical and experimental, 2002, Volume: 51, Issue:4

    Topics: Adult; Carcinoma, Hepatocellular; Creatinine; Dose-Response Relationship, Drug; Humans; Hypoxanthine

2002
Frequency and causes of hypouricemia in hospital patients.
    Israel journal of medical sciences, 1977, Volume: 13, Issue:5

    Topics: Adult; Aged; Burns; Female; Humans; Liver Diseases; Liver Neoplasms; Male; Middle Aged; Neoplasm Met

1977
Acute renal failure after ligation of the hepatic artery.
    Surgery, gynecology & obstetrics, 1976, Volume: 143, Issue:3

    Topics: Acute Kidney Injury; Adult; Aged; Aspartate Aminotransferases; Chemotherapy, Cancer, Regional Perfus

1976
The role of surgery in the management of unusual complications of transcatheter arterial embolization for hepatocellular carcinoma.
    World journal of surgery, 1988, Volume: 12, Issue:3

    Topics: Acute Disease; Adult; Aged; Carcinoma, Hepatocellular; Duodenum; Embolization, Therapeutic; Female;

1988
[Acute renal insufficiency caused by urate nephropathy and metastatic melanosarcoma].
    Presse medicale (Paris, France : 1983), 1986, Apr-05, Volume: 15, Issue:14

    Topics: Acute Kidney Injury; Female; Humans; Kidney Tubules; Liver Neoplasms; Melanoma; Middle Aged; Uric Ac

1986
[A case of primary hepatocellular carcinoma with hypouricemia].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1986, Volume: 75, Issue:12

    Topics: Adult; Biological Transport; Carcinoma, Hepatocellular; Humans; Kidney; Liver Neoplasms; Male; Uric

1986
Hypouricemia in liver cell carcinoma: an isolated renal tubular defect.
    The American journal of medicine, 1987, Volume: 83, Issue:1

    Topics: Biological Transport; Carcinoma, Hepatocellular; Humans; Kidney Tubules; Liver Neoplasms; Uric Acid

1987
Nitrogen metabolism and lipid peroxidation during hyperthermic perfusion of human livers with cancer.
    Cancer research, 1986, Volume: 46, Issue:11

    Topics: Amino Acids; Calcium; Creatinine; Humans; Hyperthermia, Induced; Lipid Peroxides; Liver Neoplasms; L

1986
A study on the sensitivity test of cancer cells to anticancer drugs.
    The Tohoku journal of experimental medicine, 1966, Jul-25, Volume: 89, Issue:3

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Carcinoma, He

1966
Therapy for carcinoma of the liver.
    The American journal of gastroenterology, 1971, Volume: 56, Issue:4

    Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Angiography; Aspartate Aminotransferases; Carcino

1971
Hepatic xanthine dehydrogenase activity and plasma uric acid concentrations of chicks with lymphoid tumor-induced anemia.
    American journal of veterinary research, 1974, Volume: 35, Issue:7

    Topics: Anemia; Animals; Chickens; Liver; Liver Neoplasms; Lymphoma; Neoplasm Transplantation; Poultry Disea

1974